Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Gefitinib IP 250 mg Tablet
Therapeutic Category
Oncology, Anticancer
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
GEFISOL 250 Tablet (Gefitinib IP 250 mg) is a crucial oral oncological medicine, belonging to the class of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). It is specifically indicated as first-line therapy for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors harbor specific EGFR-TK activating mutations (such as exon 19 deletions or L858R substitution).
The drug works by blocking the intracellular phosphorylation required for tumor cell survival and proliferation, thereby interfering with the growth and spread of cancer cells. As a highly selective targeted agent, Gefitinib offers significant improvements in progression-free survival (PFS) and a more favorable tolerability profile compared to traditional chemotherapy in mutation-positive patients.
The market for targeted cancer therapies is growing exponentially, driven by rising NSCLC incidence and mandatory genetic screening. Securing the distribution rights for a specialized, high-cost medicine like GEFISOL 250 positions you at the forefront of the profitable Oncology segment. We offer an exclusive PCD Pharma Franchise opportunity with complete Monopoly Rights in your territory. Partner with us for a high-value product, ethical business practices, assured stock availability, and dedicated promotional support targeting oncologists and specialty hospitals.
May cause headache, muscle pain, nausea, abdominal discomfort, or mild liver enzyme elevation. Rarely, serious muscle problems (myopathy or rhabdomyolysis) may occur.
Primary hypercholesterolemia Mixed dyslipidemia Familial hypercholesterolemia Prevention of cardiovascular disease in high-risk patients
Take under medical supervision, preferably once daily, with or without food. Regular liver function and lipid profile monitoring is advised. Inform your doctor about any muscle pain, weakness, or pre-existing liver/kidney conditions. Avoid excessive alcohol intake.
Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin 10 mg + Aspirin 75 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 10 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin (5mg) tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin 20 mg + fenofibrate 160 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Gefitinib 250mg Tablet has strong demand in the oncology and targeted cancer therapy segment, making it a high-value product for medical distributors, wholesalers, and pharma franchise partners focusing on oncology hospitals, specialty clinics, and critical-care portfolios.
Medical distributors and agencies can benefit from consistent demand for management of non-small cell lung cancer (NSCLC) with EGFR mutation-positive status under oncologist supervision. Gefitinib 250mg is a targeted EGFR tyrosine kinase inhibitor (TKI) used in advanced cancer therapy Widely prescribed in specialized oncology treatment protocols This strengthens a reliable oncology and specialty-care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Gefitinib 250mg Tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from high-value oncology demand, specialty hospital supply opportunities, oncologist prescriptions, reliable supply chain support, and strong margins in targeted cancer therapy medicines.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.